Over the course of my career, I’ve been privileged to serve in roles that blend scientific discovery, corporate leadership, and global health impact. From developing the first anti-TNF inhibitor to founding multiple biotech companies and leading critical medical research in the U.S. Navy, my work has always centered on advancing therapies that change lives. I’m excited to share a detailed look at my professional journey, values, and vision for the future. Here is my biography.

After decades of experience in pharmaceutical marketing, brand strategy, and digital health innovation, I’ve taken a moment to reflect on my journey—from my early days launching interactive tools at Merck, to founding CAP Pharma and leading global omnichannel campaigns. It’s been a privilege to contribute to healthcare transformation, partner with exceptional teams, and remain committed to patient-centered progress. Here is my biography.

After more than three decades dedicated to advancing veterinary oncology, translational research, and compassionate clinical care, I’m honored to share this comprehensive view of my professional journey. From pioneering cancer immunotherapies to mentoring the next generation of oncologists, my mission has always centered on improving lives—both animal and human—through innovation and collaboration. Here is my biography.

Miguel Nogueras is a globally recognized executive leader in microbiological quality and sterility assurance, known for driving innovation, regulatory excellence, and inclusive leadership across the pharmaceutical, medical device, and consumer health industries. With more than two decades of experience, he has built and led high-performing global teams, established end-to-end quality systems, and introduced advanced contamination control strategies that ensure patient safety and accelerate product delivery. Fluent in multiple languages and deeply committed to mentorship and diversity, Miguel blends scientific expertise with business acumen to deliver sustainable, compliant, and forward-thinking solutions in dynamic global markets.

I’m a pharmacist and consultant with over 25 years of experience spanning the pharmaceutical industry, regulatory affairs, and academia. My career has been driven by a passion for translating complex regulatory requirements into clear, actionable strategies that help companies innovate responsibly. Through leadership roles in both industry and consulting, I’ve had the privilege of mentoring professionals, teaching at top pharmacy schools, and partnering with organizations to align science, compliance, and strategic growth. I’m always excited to connect with others who are committed to elevating healthcare and advancing thoughtful, compliant innovation.

I’m a physician, author, and advocate with over four decades of experience in pediatric oncology, academic medicine, and nonprofit leadership. For the majority of my career, I served at Columbia University Medical Center, where I led one of the nation’s top pediatric hematology-oncology programs and mentored a generation of physician-scientists. I’m proud to have founded the Hope & Heroes Children’s Cancer Fund, which has raised over \$100 million to support children and families facing cancer. Today, I remain active as a writer and fundraiser, committed to advancing care, research, and hope for the next generation.

I'm a biotech executive and scientist with a passion for advancing oncology therapeutics from discovery through clinical development. Over the course of my career, I’ve led R\&D strategy and operations in organizations ranging from early-stage startups to large global pharma, including Takeda, ImmunoGen, Novartis, and Biogen. I’ve had the privilege of building high-performing teams, guiding complex portfolios, and contributing to therapies that make a real difference for patients. Today, I enjoy advising innovative biotech companies and VCs as they shape the next generation of cancer treatments.

After more than 30 years immersed in the world of cell and gene therapy, I've had the privilege to lead, innovate, and mentor across academic, clinical, and industry landscapes. From cleanroom design to regulatory submissions and teaching future leaders, my journey has been defined by purpose and progress. Here is my biography.

Dr. Gilles Besin is a visionary scientific executive whose career spans over 20 years at the forefront of RNA therapeutics and immunology. As Chief Scientific Officer at Orbital Therapeutics, he is redefining the landscape of next-generation RNA medicine through groundbreaking work in mRNA and circular RNA platforms. From leading vaccine development programs to spearheading major biotech acquisitions, Dr. Besin blends deep scientific expertise with strategic insight, positioning him as a driving force in translating cutting-edge research into real-world therapeutic solutions.

I’m excited to share a professional biography that reflects my journey across the biotech and pharma industries—from hands-on research to strategic leadership. It's been a privilege to work with exceptional teams, lead impactful projects, and help bring new therapies closer to the patients who need them most.

I’m excited to share my professional biography that reflects my journey through science, leadership, and global agricultural innovation. It’s been a rewarding path—from mentoring young scientists to leading multi-national research teams and contributing to groundbreaking biotechnology.

I'm excited to share my professional biography, capturing the journey I've taken across HEOR, pharmaceutical innovation, real-world evidence, and health policy. With over 20 years of experience in building value through data, strategic insight, and collaborative leadership, I'm proud to continue this work alongside inspiring teams and partners.

Ross Bundy is a pioneering biotechnology leader driving innovation in biosensor technology and genome editing optimization. As the CEO of CRISPR QC and co-founder of Cardea Bio Inc., he has been instrumental in developing platforms that enable real-time biological insights through the "Internet of Biology." With expertise in business development, financial strategy, and operational management, Bundy has successfully scaled multiple companies and forged key industry partnerships. His visionary leadership and strategic execution continue to shape the future of biotechnology, advancing diagnostics, therapeutics, and bioinformatics with cutting-edge solutions.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Thrilled to share my professional biography, which captures the arc of my 30+ year journey across life sciences, innovation, strategy, and global health. I’ve had the honor of collaborating with visionary leaders and organizations to unlock transformative value at the intersection of science, business, and impact.

Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.